MORRISVILLE, N.C. — iOrganBio, an innovator in intelligent cell manufacturing, today announced the appointment of Lee L. Rubin, Ph.D., to its Scientific Advisory Board. Dr. Rubin, a leading authority in stem cell biology, regenerative medicine, and translational neuroscience, will help guide the company's efforts to apply its CellForge platform to neurological applications.
Dr. Rubin is Co-Director and Principal Faculty of the Harvard Stem Cell Institute and Professor in Harvard’s Department of Stem Cell and Regenerative Biology. His pioneering research has advanced the understanding of neurodegenerative diseases and contributed to the development of therapeutic candidates for Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and spinal muscular atrophy (SMA). His work also spans blood-brain barrier biology, neural stem cell differentiation, and disease modeling using patient-derived induced pluripotent stem cells.
“Dr. Rubin’s deep expertise in stem cell biology and translational neuroscience is invaluable as we expand our platform into neurological disease modeling and therapy development,” said iOrganBio CEO. “His insights will accelerate our mission to provide consistent, scalable human cell models for research and therapeutic applications.”
iOrganBio’s CellForge platform combines AI prediction, biological sensing, and automated 3D incubation to engineer human cells and organoids with greater precision and consistency. The platform enables scalable production for disease modeling, drug discovery, and cell therapy development. At its core is the functional human CellAtlas™, a comprehensive reference built from single-cell and multi-omics data that provides digital blueprints for each cell type.
Dr. Rubin stated, “iOrganBio’s approach to intelligent cell manufacturing has the potential to transform how we study neurological diseases and develop therapies. I look forward to contributing to the advancement of this technology.”
The appointment comes as iOrganBio continues to expand its scientific advisory board and advance its platform for FDA-aligned New Approach Methodologies (NAMs). For more information, visit iOrgan.Bio.
